Skip to content

Advertisement

  • Oral presentation
  • Open Access

0312. Host genetics of HCV disease — IL28B

  • J Fellay1
Journal of the International AIDS Society201013(Suppl 4):O30

https://doi.org/10.1186/1758-2652-13-S4-O30

Published: 8 November 2010

Keywords

HepatitisChronic HepatitisTheoretical ImplicationClinical Trial DesignAccurate Predictor

Co-infections with HCV and HIV are common, because both viruses share routes of transmission and establish chronic infections. The standard treatment for chronic hepatitis C, a combination of peginterferon-α and ribavirin, is poorly tolerated and only successful in about half of the treated patients. Thus, identification of accurate predictors of treatment response is highly desirable.

Several independent genome-wide association studies have recently identified human genetic variants around the IL28B gene (coding for IFN-λ3) that strongly associate with spontaneous clearance of HCV and with treatment success, both in HCV mono-infected and in co-infected patients. I will put these findings in perspective and discuss their practical and theoretical implications with regard to drug development, clinical trial design and clinical management of chronic HCV infection. Results of detailed genetic and functional analyses of the IL28B gene region will also be presented.

Authors’ Affiliations

(1)
Institute of Microbiology and Service of Infectious Diseases, University of Lausanne, Geneva, Switzerland

Copyright

© Fellay; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement